Bigul

CIPLA LTD. - 500087 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

In compliance with the provisions of Regulation 30 (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby notify that the Operations and Administrative Committee of the Company on 15th April 2024 has allotted 27,906 fully paid-up equity shares of INR 2 each, pursuant to exercise of ESOPs under the Employee Stock Option Scheme 2013-A of the Company. Consequently, the issued, subscribed and paid-up Capital of the Company stands increased to INR 1,61,47,89,936 comprising of 80,73,94,968 equity shares of face value INR 2 each.
16-04-2024

Cipla's India arm inks business transfer agreement with Ivia Beaute; shares trade flat

Cipla Share Price: A meeting of the board of directors of the company will be held on May 10, 2024, to consider and approve the standalone and consolidated audited financial results.
16-04-2024
Bigul

CIPLA LTD. - 500087 - Announcement under Regulation 30 (LODR)-Acquisition

Acquisition of a business undertaking from Ivia Beaute Private Limited, India
15-04-2024
Bigul

CIPLA LTD. - 500087 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the schedule of Earnings Conference Call to be held on 10th May 2024.
05-04-2024
Bigul

CIPLA LTD. - 500087 - Board Meeting Intimation for Quarter And Year Ended 31St March 2024 Under SEBI Listing Regulations

CIPLA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/05/2024 ,inter alia, to consider and approve 1. Consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and year ended 31st March 2024. 2. Recommend final dividend for the year ended 31st March 2024, if any. In terms of the Company's Code of Conduct for Prevention of Insider Trading, the 'Trading Window' for dealing in the securities of the Company is closed from Monday, 1st April 2024 till Sunday, 12th May 2024 (both days inclusive) for the purpose of financial results.
05-04-2024

US FDA's 6 observations for Cipla's Patalganga unit drags firm's shares down 1.5%

Cipla's Patalganga plant manufactures active pharmaceutical ingredients (APIs), the key raw materials for medicines, as well as formulations.
05-04-2024
Bigul

CIPLA LTD. - 500087 - USFDA Inspection At Company'S Manufacturing Facility In Patalganga, Maharashtra, India

USFDA inspection at Company''s manufacturing facility in Patalganga, Maharashtra, India
04-04-2024

Complex respiratory portfolio propels Cipla towards profitability

A report from brokerage firm Sharekhan highlighted key factors contributing to Cipla's upward trajectory, emphasizing the company's strategic focus on complex products and the resultant impact on margins.
31-03-2024

Cipla, Sanofi India shares gain on distribution agreement

Cipla will be responsible for the distribution of Sanofi India's six central nervous system products, including Frisium, a leading brand in the anti-epileptic medication category
27-03-2024
Bigul

CIPLA LTD. - 500087 - Announcement under Regulation 30 (LODR)-Change in Management

Pursuant to Regulation 30 of the SEBI Listing Regulations, we hereby notify that Mr. Rajeev Kumar Sinha, presently working as Global Head - Formulations Manufacturing, has been appointed as Senior Management Personnel and Global Chief Manufacturing Officer w.e.f. 1st April 2024.
26-03-2024
Next Page
Close

Let's Open Free Demat Account